{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:03:00Z","timestamp":1781708580758,"version":"3.54.5"},"reference-count":23,"publisher":"Norwegian Medical Association","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.22.0043","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T09:05:02Z","timestamp":1666775102000},"source":"Crossref","is-referenced-by-count":0,"title":["Melanoma \u2013 investigation and primary treatment"],"prefix":"10.4045","volume":"142","author":[{"given":"\u00c5shild","family":"Berentzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Brevig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truls","family":"Ryder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Winge-Main","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"ref=1","unstructured":"Kreftregisteret. Melanom i hud. https:\/\/www.kreftregisteret.no\/Temasider\/kreftformer\/melanom\/ Lest 9.5.2021."},{"key":"ref=2","unstructured":"Helsedirektoratet. Maligne melanomer \u2013 handlingsprogram. Nasjonal faglig retningslinje. https:\/\/www.helsedirektoratet.no\/retningslinjer\/maligne-melanomer-handlingsprogram Lest 9.5.2021."},{"key":"ref=3","unstructured":"Nasjonalt kvalitetsregister for melanom. \u00c5rsrapport 2020. https:\/\/www.kvalitetsregistre.no\/sites\/default\/files\/2021-10\/%C3%85rsrapport%20Nasjonalt%20kvalitetsregister%20for%20melanom%202020.pdf Lest 7.9.2022."},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Robsahm\u00a0TE, Helsing\u00a0P, Nilssen\u00a0Y et al. High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry. Clin Epidemiol 2018; 10: 537\u201348. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29780262&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2147%2FCLEP.S151246","DOI":"10.2147\/CLEP.S151246"},{"key":"ref=5","unstructured":"Haenssle\u00a0HA, Korpas\u00a0B, Hansen-Hagge\u00a0C et al. Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch Dermatol 2010; 146: 257\u201364. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20231495&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Farchdermatol.2009.370"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Boniol\u00a0M, Autier\u00a0P, Boyle\u00a0P et al. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012; 345: e4757. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22833605&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fbmj.e4757","DOI":"10.1136\/bmj.e4757"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Aitken\u00a0JF, Youlden\u00a0DR, Baade\u00a0PD et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer 2018; 142: 1528\u201335. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29105744&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fijc.31141","DOI":"10.1002\/ijc.31141"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Pampena\u00a0R, Kyrgidis\u00a0A, Lallas\u00a0A et al. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77: 938\u2013945.e4. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28864306&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jaad.2017.06.149","DOI":"10.1016\/j.jaad.2017.06.149"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Gachon\u00a0J, Beaulieu\u00a0P, Sei\u00a0JF et al. First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005; 141: 434\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15837860&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Farchderm.141.4.434","DOI":"10.1001\/archderm.141.4.434"},{"key":"ref=10","unstructured":"DermNet. Melanoma of the nail unit. https:\/\/dermnetnz.org\/topics\/melanoma-of-the-nail-unit Lest 12.5.2022."},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Swetter\u00a0SM, Thompson\u00a0JA, Albertini\u00a0MR et al. NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 2021; 19: 364\u201376. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33845460&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.6004%2Fjnccn.2021.0018","DOI":"10.6004\/jnccn.2021.0018"},{"key":"ref=12","unstructured":"Verdens helseorganisasjon. WHO Classification of skin tumours. Lyon: WHO,2018: 66-75. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/WHO-Classification-Of-Skin-Tumours-2018 Lest 7.9.2022."},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Busam G. Scolyer. Pathology of melanocytic tumors. Elsevier 2019: 398-9.","DOI":"10.1016\/B978-0-323-37457-6.00033-X"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Curti\u00a0BD, Faries\u00a0MB. Recent Advances in the Treatment of Melanoma. N Engl J Med 2021; 384: 2229\u201340. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34107182&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMra2034861","DOI":"10.1056\/NEJMra2034861"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Yao\u00a0K, Balch\u00a0G, Winchester\u00a0DJ. Multidisciplinary treatment of primary melanoma. Surg Clin North Am 2009; 89: 267\u201381, xi. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19186240&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.suc.2008.11.002","DOI":"10.1016\/j.suc.2008.11.002"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Leiter\u00a0U, Stadler\u00a0R, Mauch\u00a0C et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol 2019; 37: 3000\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31557067&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.18.02306","DOI":"10.1200\/JCO.18.02306"},{"key":"ref=17","unstructured":"Broman\u00a0KK, Hughes\u00a0TM, Dossett\u00a0LA et al. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. J Am Coll Surg 2021; 232: 424\u201331. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33316427&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jamcollsurg.2020.11.014"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67(6):472-92.","DOI":"10.3322\/caac.21409"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Luke\u00a0JJ, Ascierto\u00a0PA, Carlino\u00a0MS et al. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol 2020; 16: 4429\u201338. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31870188&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2217%2Ffon-2019-0666","DOI":"10.2217\/fon-2019-0666"},{"key":"ref=20","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-adjuvant-treatment-stage-iib-or-iic-melanoma Lest 31.8.2022."},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Weber\u00a0J, Mandala\u00a0M, Del Vecchio\u00a0M et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377: 1824\u201335. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28891423&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1709030","DOI":"10.1056\/NEJMoa1709030"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Eggermont\u00a0AMM, Blank\u00a0CU, Mandala\u00a0M et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018; 378: 1789\u2013801. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29658430&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1802357","DOI":"10.1056\/NEJMoa1802357"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Long\u00a0GV, Hauschild\u00a0A, Santinami\u00a0M et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377: 1813\u201323. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28891408&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1708539","DOI":"10.1056\/NEJMoa1708539"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Melanom \u2013 utredning og prim\u00e6rbehandling"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:29:31Z","timestamp":1781706571000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2022\/10\/klinisk-oversikt\/melanom-utredning-og-primaerbehandling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":23,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,10,25]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.22.0043","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]}}}